Sensory-specific Peripheral Stimulation for Tremor Management
Launched by SHIRLEY RYAN ABILITYLAB · Aug 5, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a method called peripheral electrical stimulation (PES) to help manage tremors in people with Parkinson's Disease or Essential Tremor. Researchers want to understand how this treatment works by studying brain activity and muscle responses using various techniques, including brain scans and electrical tests. The study is open to both healthy individuals and patients aged 18 to 80 who have been diagnosed with either Essential Tremor or Parkinson's Disease and experience significant tremors in their arms.
To participate, healthy volunteers should have no neurological disorders or tremors, while patients need to have moderate to severe tremors that affect their daily life. Participants will undergo several non-invasive tests to assess their tremor and brain function. It's important to note that certain medical conditions, devices, or medications may exclude someone from joining the study, so potential participants should review the eligibility criteria carefully. Overall, this trial aims to explore a new option for helping those who struggle with tremors, potentially improving their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for Healthy Participants:
- • Age from 18 to 80 years
- • No history of a brain and/or skull lesion
- • Normal hearing and (corrected) vision
- • Able to understand and give informed consent
- • No neurological disorders, no tremor
- • Absence of pathology that could cause abnormal movements of extremities (e.g., epilepsy, stroke, marked arthritis)
- • Able to understand and speak English
- Inclusion Criteria for Patients:
- • Age from 18 to 80 years
- • No prior history of skull lesions or craniotomy
- • Normal hearing and (corrected) vision
- • Able to understand and give informed consent
- • Diagnosis of ET (Tremor Research investigation Group criteria) or diagnosis of PD (UK PD Society Brain bank diagnostic criteria) by a physician
- • Tremor in at least an upper limb with pure flexion-extension wrist tremor with posture (ET) and rest (PD).
- • Tremor at least moderate-severe by clinician judgment and tremor scales (Fahn Tolosa Marin Tremor Rating Scale (TETRAS), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS))
- • Absence of pathology that could cause abnormal movements of extremities (e.g., epilepsy, stroke, marked arthritis, moderate to severe dyskinesias in PD)
- • Stable medication doses for at least 30 days prior to study enrollment
- • Able to understand and speak English
- Exclusion Criteria for Healthy Participants:
- • Cardiac pacemaker or pacemaker wires; neurostimulators; implanted pumps
- • Metal in the body (rods, plates, screws, shrapnel, dentures, IUD) or metallic particles in the eye
- • Surgical clips in the head or previous neurosurgery
- • Any magnetic particles in the body
- • Cochlear implants
- • Prosthetic heart valves
- • Epilepsy or any other type of seizure history
- • Any neurological diagnoses or medications influencing brain function
- • History of significant head trauma (i.e., extended loss of consciousness, neurological sequelae)
- • Known structural brain lesion
- • Significant other disease (heart disease, malignant tumors, mental disorders)
- • Significant claustrophobia; Ménière's disease
- • Pregnancy (ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy is possible), breast feeding
- • Non prescribed drug use
- • History of current substance abuse (exception: current nicotine use is allowed)
- • Recreational marijuana
- • Tremor, parkinsonism; neurological diseases; medical (cardiological, renal, hepatic, oncological) or psychiatric disease that would interfere with study procedures for asES, HD-EMG, TMS, or EEG
- • Dementia; severe depression; or prior neurosurgical procedures
- • Failure to perform the behavioral tasks or neuropsychological evaluation tests
- • Prisoners
- Exclusion Criteria for Patients:
- • Cardiac pacemaker or pacemaker wires; neurostimulators; implanted pumps
- • Metal in the body (rods, plates, screws, shrapnel, dentures, IUD) or metallic particles in the eye
- • Surgical clips or shunts in the head
- • Any magnetic particles in the body
- • Cochlear implants
- • Prosthetic heart valves
- • Epilepsy or any other type of seizure history
- • Significant claustrophobia; Ménière's disease
- • Pregnancy, breast feeding
- • Medications increasing risk for seizures
- • History of current substance abuse (exception: current nicotine use is allowed)
- • Failure to perform tasks (e.g., follow instructions to stay still in the scanner) or fill in safety screening forms
- • Prisoners
- • Atypical or secondary parkinsonism
- • Co-existence of other neurological diseases
- • Mixed or complex tremors
- • Inability or unwillingness to discontinue medications for tremor on the day of study assessments
- • Medical (cardiological, renal, hepatic, oncological) or psychiatric disease that would interfere with study procedures for asES, HD-EMG, TMS, or EEG; dementia; severe depression; prior neurosurgical procedures
About Shirley Ryan Abilitylab
Shirley Ryan AbilityLab is a leading research and rehabilitation institute dedicated to advancing the science of physical medicine and rehabilitation. Based in Chicago, Illinois, the organization integrates clinical care, research, and education to enhance the quality of life for individuals with disabilities and chronic conditions. Known for its innovative approach, Shirley Ryan AbilityLab conducts clinical trials that aim to develop and evaluate cutting-edge therapies and technologies, fostering a collaborative environment that bridges the gap between laboratory research and patient care. Through its commitment to excellence, the institute strives to empower patients and improve outcomes in rehabilitation medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Jose Pons, Ph.D
Principal Investigator
Shirley Ryan AbilityLab
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials